Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Mar 11, 2020
Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the
Mar 03, 2020
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays
Feb 27, 2020
BLA for ROLONTIS ® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11 th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call
Feb 20, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 20, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial
Feb 06, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 6, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Dec 26, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 26, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously
Nov 14, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Nov 07, 2019
Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center
Oct 31, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 31, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019 financial results, provide an
Oct 24, 2019
ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive
Oct 04, 2019
  Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated cancers     HENDERSON, Nev. --(BUSINESS WIRE)--Oct.
Sep 25, 2019
  HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 25, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the 2019
Sep 06, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 6, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond.
Sep 03, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 3, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at two upcoming
Aug 08, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 8, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019 .
Aug 01, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 1, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on
Jul 22, 2019
Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypical EGFR or
Jun 20, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 20, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms.
Jun 02, 2019
Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data demonstrated that eflapegrastim provided an absolute risk reduction of severe neutropenia of 6.5% compared to pegfilgrastim in Cycle 1 HENDERSON, Nev.
May 29, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York .
Displaying 21 - 40 of 818